Forget Bydureon. Sell byetta and symlin. It's an exenatide quota....and symlin counts as much as Bydureon for pay and rank. The best part is both have great coverage and headquarters won't bait and switch incentive comp for byetta and symlin. They sure will for Bydureon, like in Q1. Whatever will benefit Amylin's sale.